Safety and tolerability of oral administration of our fourth generation macrolide.

Cempra’s solithromycin demonstrates efficacy much like levofloxacin for CABP treatment Today announced results from its Phase II clinical trial investigating the efficacy Cempra Pharmaceuticals, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin , a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treating community-acquired bacterial pneumonia .D., Shields Warren-Mallinckrodt Professor of Medical Analysis at Harvard Medical School. David Oldach, M.D., senior vice president of clinical study of Cempra added, Outcomes out of this trial indicate that CEM-101 is a product candidate with efficacy much like levofloxacin, the existing standard of care for the treatment of CABP and with a favorable protection profile.

CenTrak gives Bluetooth Low Energy to Clinical-Grade RTLS platform CenTrak today announced that Bluetooth Low Energy has been added to its widely adopted Clinical-Grade RTLS platform, with the first installations occurring this full month. This patent-pending fully integrated BLE technology offers a uniquely well maintained and dependable architecture. BLE has an increasingly ubiquitous presence on smartphones and additional mobile devices, and offers the ability to incorporate embedded BLE technology obtainable through other infrastructure suppliers. This feature enables an immediate dialogue between CenTrak's RTLS and nonproprietary devices.